Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $34.00 price target on the stock.
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee [Yahoo! Finance]
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target lowered by analysts at Citigroup Inc. from $32.00 to $30.00. They now have a "buy" rating on the stock.